GlassScriptPhysician profile
Jaskiran Kaur
NPI 1619545241
$1,128.96
in general payments reported to CMS, 2019-2025
13 companies · $33.70 in 2025
The $33.70 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $344 · 2023: $259 · 2024: $375 · 2025: $33.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $308.06 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $171.87 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $125.00 | 2024 | Meibomian Gland Evaluator, Lipiflow System Activator (Disposable) |
| Alcon Vision LLC | $119.36 | 2022-2023 | Rocklatan, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.80 | 2021 | |
| Dompe US, INC. | $67.78 | 2023 | Oxervate |
| Oyster Point Pharma, INC. | $51.39 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $47.48 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $42.57 | 2023-2024 | Vyzulta, Miebo, Xiidra |
| Abbvie INC. | $34.98 | 2023 | |
| Biotissue Holdings INC. | $28.91 | 2021 | |
| Rxsight INC | $23.17 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $20.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskiran Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.